Schwarzach

Researchers are conducting a global observational study called the InRAD Registry to collect long-term real-world data on people with Alzheimers disease PwAD. The study aims to better understand disease progression, treatment safety, and outcomes across different countries by gathering medical information from routine clinical practice. This study includes adults undergoing diagnosis or already diagnosed with Alzheimers disease, including those treated, eligible for treatment, or untreated. Participants attend their regular doctor visits, such as with psychiatrists, geriatricians, or neurologists, at least once a year or as needed for care. Data is collected through a cloud-based platform, including patient demographics, disease characteristics, clinical outcomes, safety information, and treatment details. Additional data like lifestyle factors, biomarkers, and quality of life assessments may also be collected. The study does not involve any experimental treatments and only observes routine care. Participants will be followed over many years, with data collected at least annually and submitted biannually. The study records changes in Alzheimers disease clinical staging over time and monitors serious adverse events related to treatments. There is no additional cost for participation, but usual care and treatment costs are covered by patients or their health insurance. The study aims to support research that improves understanding and management of Alzheimers disease worldwide.